Specializing in innovative medical devices, this company focuses on neurovascular and peripheral vascular conditions, offering products like thrombectomy systems and embolic coils. Investors monitor Penumbra for its growth in minimally invasive treatments and competitive position in the $13B+ vascular access market.
3 members of Congress have disclosed 6 trades in Penumbra, Inc. (PEN), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-07-10 | Lisa McClain | sell | $1K – $15K |
| 2022-04-21 | MICHAEL T. MCCAUL | buy | $50K – $100K |
| 2017-11-28 | JAMES B. RENACCI | buy | $1K – $15K |
| 2017-01-13 | JAMES B. RENACCI | buy | $15K – $50K |
| 2016-12-13 | JAMES B. RENACCI | buy | $15K – $50K |
| 2016-11-22 | JAMES B. RENACCI | buy | $15K – $50K |